Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus

Journal of Infectious Diseases

Volumn 198, Issue 8, 2008, Pages 1150-1158

  Ohkawa, Kazuyoshi ^a   Takehara, Tetsuo ^a   Kato, Michio ^c   Deguchi, Matsuo ^b   Kagita, Masanori ^b   Hikita, Hayato ^a   Sasakawa, Akira ^a   Kohga, Keisuke ^a   Uemura, Akio ^a   Sakamori, Ryotaro ^a   Yamaguchi, Shinjiro ^a   Miyagi, Takuya ^a   Ishida, Hisashi ^a   Tatsumi, Tomohide ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE DELETION; GENE EXPRESSION SYSTEM; GENE MUTATION; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO GENE TRANSFER; MALE; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; VIRUS GENE; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOME, VIRAL; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN PRECURSORS; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

EID: 54749091200     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591941     Document Type: Article

References (34)

1. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-8.
2. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-63.
3. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. Adefovir Dipivoxil 438 Study Group. N Engl J Med 2003; 348:800-7.
4. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Adefovir Dipivoxil 437 Study Group. N Engl J Med 2003; 348:808-16.
5. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. BEHoLD AI463022 Study Group. N Engl J Med 2006; 354:1001-10.
6. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. BEHoLD AI463027 Study Group. N Engl J Med 2006; 354:1011-20.
7. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421-5.
8. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005; 43:60-6.
9. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Telbivudine Phase II Investigator Group. Gastroenterology 2005; 129:528-36.
10. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40:140-8.
11. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-96.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Adefovir Dipivoxil 438 Study Group. Gastroenterology 2006; 131:1743-51.
13. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44:1656-65.
14. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51:902-11.
15. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670-7.
16. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-72.
17. Westland CE, Yang H, Delaney WE 4th, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12:67-73.
18. Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103:1635-40.
19. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-33.
20. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107:449-55.
21. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34:584-6.
22. Kanada A, Takehara T, Ohkawa K, et al. Type B fulminant hepatitis is closely associated with a highly mutated hepatitis B virus strain. Intervirology 2007; 50:394-401.
23. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16:111-20.
24. Saitou N, Nei M. The neighbor-joining method: a new method for estimating and testing minimum-evolution trees. Mol Biol Evol 1987; 4:406-25.
25. Fujiyama A, Miyanohara A, Nozaki C, Yoneyama T, Ohtomo N, Matsubara K. Cloning and structural analyses of hepatitis B virus DNAs, subtype adr. Nucleic Acids Res 1983; 11:4601-10.
26. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588-91.
27. Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64:1298-303.
28. Delaney WE 4th, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77:11833-41.
29. Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37:27-35.
30. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J Virol 2004; 78:8524-35.
31. Tong SP, Diot C, Gripon P, et al. In vitro replication competence of a cloned hepatitis B virus variant with a nonsense mutation in the distal pre-C region. Virology 1991; 181:733-7.
32. Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44:326-34.
33. Sugauchi F, Ohno T, Orito E, et al. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 2003; 70:537-44.
34. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-8.